Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102113 · ClinicalTrials.gov registry record · Early Phase 1
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
A Early Phase 1 study of Schizophrenia and Cannabis Use, sponsored by Yale University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02102113 is a Early Phase 1 study of Schizophrenia and Cannabis Use that is active but no longer recruiting, run by Yale University. The registered enrollment target is 21 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02102113, a Early Phase 1 study of Schizophrenia and Cannabis Use, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Very Low Dose THC
- DRUG Low Dose THC
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-01 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02102113
The ClinicalTrials.gov registry entry for NCT02102113 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (90% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02102113 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02102113 about?
NCT02102113 is a clinical study titled "Probing the Cannabinoid System in Individuals With a Family History of Psychosis". The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a ...
What is the current status of trial NCT02102113?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2014-01. Estimated completion is 2026-12.
What conditions does trial NCT02102113 study?
This clinical trial studies the following conditions: Schizophrenia, Cannabis Use, Psychosis, THC, Marijuana.
What interventions are being tested in trial NCT02102113?
The interventions under investigation include: Placebo (DRUG), Very Low Dose THC (DRUG), Low Dose THC (DRUG).
Who is sponsoring clinical trial NCT02102113?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02102113 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.